
ArcticZymes Technologies Investor Relations Material
Latest events

Q2 2025
ArcticZymes Technologies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ArcticZymes Technologies
Access all reports
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and markets recombinant enzymes derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics, and therapeutics in Norway, Europe, Asia, Australia, Africa, and the Americas. It provides enzymes for real-time PCR; enzymes for various applications; Norzym Taq DNA Polymerase for routine PCR applications; Menthazym Taq DNA Polymerase that enables amplification of DNA in low-copy templates; Toyzym Taq DNA Polymerase that enhances PCR sensitivity and specificity; MgGapFill DNTP Mix that produces more reliable qPCR results by maximizing efficiency and reducing nonspecific amplifications; and ZymoTaq Hotstart qPCR Mix that provides speed and convenience with the increased specificity of hot-start chemistry.
Key slides for ArcticZymes Technologies


Q2 2025
ArcticZymes Technologies


Pareto Securities Healthcare Conference Presentation
ArcticZymes Technologies
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
AZT
Country
🇳🇴 Norway